The Journal of the Institute of Materia Medica, the Chinese Academy of Medical Sciences and the Chinese Pharmaceutical Association Peer Review under the responsibility of Institute of Materia Medica, Chinese Academy of Medical Sciences and Chinese Pharmaceutical AssociationActa Pharmaceutica Sinica B (APSB) is a monthly journal, in English, which publishes significant original research articles, rapid communications and high quality reviews of recent advances in all areas of pharmaceutical sciences including pharmacology, pharmaceutics, medicinal chemistry, natural products, pharmacognosy, pharmaceutical analysis and pharmacokinetics.APSB is a series of journal of Acta Pharmaceutica Sinica, which was founded in 1953, indexed in Chemical Abstracts, Index Medicus, SciFinder Scholar, Biological Abstracts, International Pharmaceutical Abstracts, Cambridge Scientific Abstracts, Current Bibliography on Science and Technology, etc. It sponsored by Insititute of Materia Medica, Chineses Acedemy of Medical Sciences and Chinese Pharmaceutical Association, production and hosting by Elsevier B.V.
Peer Review under responsibility of Shenyang Pharmaceutical UniversityAsian Journal of Pharmaceutical Sciences (AJPS) is the official journal of Asian Federation for Pharmaceutical Sciences (AFPS) and is indexed by Science Citation Index Expanded (SCIE). It provides the forum for reporting innovations, production methods, technologies, initiatives and the application of scientific knowledge to all aspects of pharmaceutics, including controlled drug release systems, drug targeting, physical pharmacy, pharmacodynamics, pharmacokinetics, pharmacogenomics, biopharmaceutics, drug and prodrug design, pharmaceutical analysis, drug stability, quality control, pharmaceutical engineering and material sciences.
Drug Resistance Updates publishes inspiring original research, commentary and expert reviews on important developments in drug resistance in infectious disease and cancer as well as novel drugs and strategies to overcome drug resistance. It covers both basic research and clinical aspects of drug resistance, and involves disciplines as diverse as molecular biology, biochemistry, cell biology, pharmacology, microbiology, preclinical therapeutics, oncology, and clinical medicine. The Editors welcome and encourage the submission of original research articles while review articles are written by leaders in the field of drug resistance by invitation.
EJMCR (European Journal of Medicinal Chemistry Reports) is an open access companion title to European Journal of Medicinal Chemistry. It is an international open access journal indexed in Scopus and the Impact Factor will be announced soon.EJMCR publishes all aspects of medicinal chemistry with a focus on drug discovery. It provides a forum for medicinal chemists both from academia and from industry to share new results and the state of the art via the publication of full research papers, reviews, microarticles and short communications. Key aspects of the scope include but are not limited to:Biologically active compoundsDrug targetingDrug-receptor interactionsMolecular aspects of biologically active compounds metabolismDrug delivery systemsHit discoveryPharmacological evaluation of known biologically active compoundsNatural productsTraditional Chinese Medicine (TCM)Novel methodology (including computational strategies and tools) and database, structural biological studies (X-ray, NMR, etc.) of relevant ligands and targets with application to medicinal chemistry
Heliyon considers research from all areas of the physical, applied, life, social and medical sciences. We publish manuscripts reporting scientifically accurate and valuable research, which adheres to accepted ethical and scientific publishing standards. As such Heliyon publishes new insights as well as extensions on existing theories, negative/null results and replication studies.Submissions covering arts, humanities and law are not considered in Heliyon. Authors of these submissions are encouraged to submit directly to our partner journal Social Sciences & Humanities Open.Heliyon classifies manuscripts/articles into different sections based on the research topic discussed. Some sections exclude certain types of studies from their scope. To know more and to see the kind of manuscripts the various sections publish, please visit: https://www.cell.com/heliyon/sectionsA dedicated in-house editorial office team, internal editors as well as external academic section and associate editors handle your manuscript and manage the publication process, giving your research the editorial support and quality control it deserves.If it's important to you, it's important to us. Submit your paper today.
International Journal of Pharmaceutics: X offers authors with high-quality research who want to publish in a gold open access journal the opportunity to make their work immediately, permanently, and freely accessible.International Journal of Pharmaceutics: X authors will pay an article publishing charge (APC), have a choice of license options, and retain copyright. Please check the APC here. The journal is indexed in SCOPUS, PUBMED, PMC and DOAJ.The International Journal of Pharmaceutics is the second most cited journal in the "Pharmacy & Pharmacology" category out of 358 journals, being the true home for pharmaceutical scientists concerned with the physical, chemical and biological properties of devices and delivery systems for drugs, vaccines and biologicals, including their design, manufacture and evaluation. This includes evaluation of the properties of drugs, excipients such as surfactants and polymers and novel materials. The journal has special sections on pharmaceutical nanotechnology and personalized medicines, and publishes research papers, reviews, commentaries and letters to the editor as well as special issues.Editorial Policy The over-riding criteria for publication are originality, high scientific quality and interest to a multidisciplinary audience. Papers not sufficiently substantiated by experimental detail will not be published. Any technical queries will be referred back to the author, although the Editors reserve the right to make alterations in the text without altering the technical content. Manuscripts submitted under multiple authorship are reviewed on the assumption that all listed authors concur with the submission and that a copy of the final manuscript has been approved by all authors and tacitly or explicitly by the responsible authorities in the laboratories where the work was carried out. If accepted, the manuscript shall not be published elsewhere in the same form, in either the same or another language, without the consent of the Editors and Publisher.Authors must state in a covering letter when submitting papers for publication the novelty embodied in their work or in the approach taken in their research. Routine bioequivalence studies are unlikely to find favour. No paper will be published which does not disclose fully the nature of the formulation used or details of materials which are key to the performance of a product, drug or excipient. Work which is predictable in outcome, for example the inclusion of another drug in a cyclodextrin to yield enhanced dissolution, will not be published unless it provides new insight into fundamental principles.